Endemic Burkitt's lymphoma (BL) is considered to preferentially develop in equatorial Africa because of chronic co-infection with Epstein-Barr virus (EBV) and the malaria pathogen Plasmodium falciparum. The interaction and contribution of both pathogens in the oncogenic process are poorly understood. Earlier, we showed that immune activation with a synthetic Toll-like receptor 9 (TLR9) ligand suppresses the initiation of EBV lytic replication in primary human B cells. In this study we investigate the mechanism involved in the suppression of EBV lytic gene expression in BL cell lines. We show that this suppression is dependent on functional TLR9 and MyD88 signaling but independent of downstream signaling elements, including phosphatidylinositol-3 kinase, mitogen-activated protein kinases and nuclear factor-jB. We identified TLR9 triggering resulting in histone modifications to negatively affect the activation of the promoter of EBV's master regulatory lytic gene BZLF1. Finally, we show that P. falciparum hemozoin, a natural TLR9 ligand, suppresses induction of EBV lytic gene expression in a dose-dependent manner. Thus, we provide evidence for a possible interaction between P. falciparum and EBV at the B-cell level and the mechanism involved in suppressing lytic and thereby reinforcing latent EBV that has unique oncogenic potential.
Introduction
Endemic Burkitt's lymphoma (BL) emerges from B cells, is the most common cancer in children in equatorial Africa and harbors Epstein-Barr virus (EBV) in 495% that, together with the malaria parasite Plasmodium falciparum, is thought to cause the oncogenesis (Rochford et al., 2005) . The possible interaction and contribution of both pathogens in this process are poorly understood.
EBV is a gammaherpesvirus that infects 490% of the human population. Primary infection largely takes place during childhood, and EBV persists in infected individuals in latently infected B cells. However, EBV may reactivate, resulting in the production of progeny virus and death of the host B cell (Cohen, 2000) . Upon reactivation, the EBV immediate-early gene BZLF1 (encoding the protein Zta), the master regulatory lytic gene, is the very first viral lytic gene expressed (Rickinson and Kieff, 2007) . It encodes transcription factors that induce an ordered cascade of early and late lytic EBV genes expressions (Tsurumi et al., 2005) . Notably, in cell lines infected with latent EBV, the virus can be induced to lytic infection by stimuli such as anti-immunoglobulin (Ig), transforming growth factor-b (TGFb), 12-O-tetradecanoylphorbol-13-acetate or sodium butyrate (SB) (Tovey et al., 1978; zur Hausen et al., 1978; Luka et al., 1979; Takada, 1984; di Renzo et al., 1994) . Expression of EBV latent genes may lead to growth transformation of B cells in vitro (Klein et al., 2007) , and endemic BL is strongly associated with latent EBV. Cell lines derived from EBV-positive BL, such as the Akata or the Mutu I cell line, are instrumental in elucidating the factors that regulate the balance between EBV latency and lytic reactivation.
Toll-like receptors (TLRs) are key components of the innate immune system and sense structural motifs of microbes (Ishii et al., 2008) . The endosomal TLR9, which is mainly expressed by B cells (Hornung et al., 2002) , can be triggered by synthetic oligodeoxynucleotide (ODN) containing unmethylated CpG, a motif found in bacterial and viral DNA (Heeg et al., 2008) . Importantly, P. falciparum also triggers TLR9 (Coban et al., 2005; Parroche et al., 2007) . Signaling of TLR9 in B cells proceeds through myeloid differentiation primary response gene (88) (MyD88), and culminates in the activation of mitogen-activated protein kinases, nuclear factor (NF)-kB and activator protein-1 complexes (Peng, 2005) . Thus, NF-kB and activator protein-1 complexes are enabled to translocate into the cell nucleus in which they promote the expression of genes involved in cell activation, proliferation and production of proinflammatory cytokines (Takeshita et al., 2004) . Moreover, it has been reported that TLRs regulate the shape and extent of the inflammatory response through chromatin modifications at the level of individual cellular promoters (Foster et al., 2007) . Recently, we have shown that triggering TLR9 results in the suppression of induction of lytic EBV and thus reinforcement of latent EBV in cord blood mononuclear cells (Ladell et al., 2007) . How TLR9 triggering interacts with and whether TLR9 triggering by P. falciparum influences EBV gene expression remain to be elucidated.
In this study we investigated the effect of TLR9 triggering and downstream signaling elements on EBV gene expression in BL model cell lines. We used Akata cells, a Japanese non-endemic BL cell line, and Mutu I cells, an African endemic BL cell line, which can be induced to enter the lytic phase by B-cell receptor (BCR) crosslinking with anti-Ig. Our data give insights of how P. falciparum might interact with EBV at the B-cell level and thus both microbes might contribute to pathogenesis of endemic BL.
Results

TLR9 triggering suppresses BCR-mediated EBV reactivation in Akata cells
To characterize the effect of TLR9 triggering on EBV lytic gene induction in BL cells, we stimulated Akata cells with ODN CpG2006 before crosslinking of the BCR with anti-IgG antibodies and measured EBV's master regulatory lytic gene BZLF1 mRNA at various time points using quantitative real-time PCR (qPCR). After BCR crosslinking, we detected a rapid increase in BZLF1 mRNA expression peaking at 4 h (Figure 1a ), which conforms with previous reports (Flemington et al., 1991; Yuan et al., 2006) . After TLR9 triggering with CpG2006, we observed a reproducible reduction (of at least threefold at 4 h) in the induced BZLF1 mRNA expression (Figure 1a ). In accordance with their chronological appearance in the EBV lytic cascade, the mRNA expression levels of the immediate-early gene BRLF1 (Figure 1b) , the early lytic gene BXLF1 (data not shown) and the late lytic genes BXLF2 (Figure 1c ) and BCRF1 (Figure 1d ) after BCR crosslinking were also strongly reduced after TLR9 triggering.
To confirm above mRNA data, we performed western blot analyses of Zta (protein expressed by BZLF1), followed by immunoprecipitation of Zta to enhance detection. Triggering TLR9 with CpG2006 reduced the BCR crosslinking-mediated Zta expression to undetectable levels (Figure 1e ). Moreover, we performed immunofluorescence microscopy for Zta, and observed a . After 2 h anti-IgG was added. Cells were harvested at indicated times, followed by quantitative real-time PCR. Results show mRNA transcripts normalized to the mRNA levels of the housekeeping gene HMBS and over unstimulated cells. (e) TLR9 triggering reduces anti-IgG-induced Zta production. Results show western blot for Zta protein with immunoprecipitation. Cells were treated with CpG2006 for 2 h, followed by anti-IgG for 6 h. One representative experiment is shown out of three independent experiments. (f) TLR9 triggering reduces the number of cells producing Zta. Cells were treated with CpG2006, followed by anti-IgG for 6 h. Zta-positive cells were detected by immunofluorescence. (g) TLR9 triggering reduces EBV copy number in the supernatant. Supernatant was harvested 48 h after CpG2006 and BCR crosslinking, followed by DNAse treatment, viral DNA isolation and quantitative real-time PCR. N ¼ 3 independent experiments. Data are represented as mean ± s.e.m. ***Level of significance was Po0.001 using unpaired Student's t-test. *Level of significance was Po0.05. ND, not detectable.
TLR9 triggering in endemic Burkitt's lymphoma L Zauner et al significant reduction in the number of cells producing observable Zta after CpG2006 treatment (Figure 1f ). To investigate whether TLR9 suppresses virus production, we measured EBV DNA copy numbers in the supernatant of Akata cells. Non-encapsidated EBV DNA is sensitive to DNAse and therefore does not originate from lytic infection but rather from dying latently infected cells (Ryan et al., 2004) . Thus, DNAse treatment was used to detect only encapsidated virus, for example, virus produced from lytic infection. Our results show that CpG2006 treatment significantly reduced EBV DNA copy numbers in supernatant, indicating suppression of EBV release (Figure 1g ).
TLR9 triggering mediates suppression of EBV lytic gene expression in BL cells provoked to switch to the lytic phase by distinct pathways To further investigate the inhibitory effect of CpG2006 on EBV lytic gene expression, we addressed the possibility of interference with initial steps in BCR signaling. BCR crosslinking leads to binding and activation of tyrosine kinases Lyn and Syk, followed by a distinct release of intracellular Ca 2 þ (Kurosaki, 1999) . Therefore, CpG ODN treatment could possibly affect levels of Lyn (Sanjuan et al., 2006) , leading to an inhibition of the Ca 2 þ flux, and thus reduce BZLF1 mRNA expression. However, when we triggered TLR9 before BCR crosslinking, the signal for Ca 2 þ release, measured by flow cytometry (Novak and Rabinovitch, 1994; Rechsteiner et al., 2008) , was as strong as after BCR crosslinking alone (Figure 2a) . Thus, TLR9 triggering does not interfere with BCR crosslinking itself or with initial steps of BCR signaling leading to Lyn activation and Ca 2 þ release. We next investigated whether the TLR9-mediated suppression of lytic EBV is also operative in other BL cell lines. We used the endemic BL cell line Mutu I in which EBV enters its lytic phase after BCR crosslinking with anti-IgM or treatment with TGFb (Tovey et al., 1978; di Renzo et al., 1994) . Triggering of TLR9 preceding BCR crosslinking or TGFb treatment significantly inhibited BZLF1 mRNA expression in Mutu I cells (Figure 2b ). Thus, TLR9-mediated suppression of EBV lytic gene expression is independent of the agent used to provoke EBV switching to its lytic phase and this suppressive effect is not restricted to a single BL cell line.
CpG2006-induced suppression of lytic EBV requires signaling through TLR9 To verify the CpG2006-induced suppression of EBV lytic gene expression, we used a control oligonucleotide that contains a GpC motif instead of the CpG motif. When we treated Akata cells with the control GpC2006 before BCR crosslinking, we detected significantly less suppression of BZLF1 expression compared with CpG2006 (Figure 3a) , and even higher concentrations of GpC (up to 20 mM) never achieved the suppression magnitude observed with 0.5 mM CpG (data not shown). The moderate suppressive effect of GpC could be because of the phosphorothioate backbone that was reported to have immune stimulatory effects independent of CpG motifs (Heeg et al., 2008) . Thus, the CpG2006 motif is responsible for the suppression of lytic EBV.
To prove that the suppressive effects of CpG2006 on EBV lytic gene expression are mediated through TLR9 signaling, we investigated the effect of the TLR9 inhibitors IRS869 and chloroquine. IRS869 competes with CpG2006 for binding to TLR9 (Ashman et al., 2005; Duramad et al., 2005) , whereas chloroquine blocks the acidification and thus the maturation of endosomes (Yi et al., 1999) . Indeed, both inhibitors reversed the suppressive effect of CpG2006 on BCR triggering-induced Data are represented as mean ± s.e.m. ***Significance relative to the mock treated control was Po0.001 using unpaired Student's t-test. **Significance relative to the mock treated control was Po0.01 using unpaired Student's t-test. Figure 3c ) and late lytic BXLF2 genes mRNA expression ( Figure 3d ). It is noteworthy that both inhibitors also blocked TLR9-induced expression of cytokines, that is, hIL10 (Figure 3e ), confirming their capacity in inhibiting TLR9 activation. Thus, signaling through TLR9 indeed mediates the suppressive effects of CpG2006 on lytic EBV.
MyD88 is required for TLR9-mediated suppression of EBV lytic gene expression
To test whether TLR9-mediated suppression of EBV lytic gene expression requires signaling through its adaptor protein MyD88 (Kumagai et al., 2008) , we stably overexpressed a dominant-negative mutant form of MyD88 in Akata cells. Overexpression was confirmed by measuring MyD88 mutant ( Figure 4a ) and MyD88 wild-type ( Figure 4b ) mRNA expression, respectively. Furthermore, TLR9-induced translocation of NF-kB into the nucleus was strongly inhibited in Akata cells stably expressing the MyD88 mutant ( Figure 4c ). Moreover, TLR9 triggering did not increase transcripts of hIL10 ( Figure 4d ) in the MyD88 mutant Akata cells. Thus, the MyD88 mutant Akata cells are apt to examine whether CpG2006-induced suppression of EBV lytic gene expression is MyD88 dependent. Indeed, in Akata cells stably expressing the MyD88 mutant, the TLR9 ligand did not inhibit BZLF1 mRNA expression ( Figure 4e ). Thus, our results show that TLR9-induced suppression of EBV lytic gene expression is dependent on the TLR9-MyD88 signaling axis.
Neither NF-kB nor other known TLR9 signaling pathways are key for the TLR9-mediated suppression of lytic EBV NF-kB has a key regulatory role in gammaherpesvirus replication; that is, activation of NF-kB inhibits mouse gammaherpesvirus (MHV68) lytic replication, whereas blocking of NF-kB leads to reactivation of human gammaherpesvirus EBV in latently infected B cells (Brown et al., 2003) . Consequently, we investigated whether the inhibitory effect of TLR9 triggering on lytic EBV is mediated by NF-kB. The BZLF1 mRNA expression induced by BCR crosslinking was significantly increased by co-treatment with the InSolution NF-kB activation inhibitor (Calbiochem, San Diego, CA, USA) compared with no co-treatment ( Figure 5a ). Unexpectedly, TLR9 triggering still significantly reduced BZLF1 mRNA expression when NF-kB activation was inhibited ( Figure 5a ), indicating that NF-kB is not the main mediator of TLR9's suppressive effect on lytic EBV. Other tested NF-kB inhibitors such as Bay11 showed similar results (data not shown). Thus, although NF-kB is involved in reducing BZLF1 mRNA expression, the inhibitory effect of TLR9 on BZLF1 mRNA expression is largely independent of NF-kB. We next investigated whether TLR9 signaling elements other than NF-kB might be involved in the suppression of BZLF1 mRNA expression. We focused on phosphatidylinositol-3 kinases, mitogen-activated protein/extracellular signal-regulated kinase kinase, extracellular signal-regulated kinase, c-Jun N-terminal kinase and p38, as they are also involved in signal transduction after BCR crosslinking (Iwakiri and Takada, 2004) . Using these inhibitors, we detected a significant suppression of BCRinduced BZLF1 expression (Figures 5b-e) . Importantly, TLR9 triggering still suppressed BZLF1 mRNA expression despite the treatment with the applied inhibitors. Notably, the inhibitors interfered with CpG-induced hIL-10 expression (data not shown). Collectively, our results showed that known TLR9 signaling elements, including NF-kB, phosphatidylinositol-3 kinase, extracellular signal-regulated kinase, c-Jun N-terminal kinase and p38, are not fully responsible for the TLR9-mediated suppression of induction of lytic EBV.
TLR9-induced histone modifications on the BZLF1 promoter mediate the suppression of lytic EBV in BL cells We investigated the possibility of BZLF1 mRNA instability being responsible for our observation after TLR9 triggering. We excluded this possibility by showing that BZLF1 mRNA is very stable over time compared with TNFa or hIL10 mRNA after CpG2006 treatment and BCR crosslinking in the presence of actinomycin D (data not shown). 
TLR9 triggering in endemic
The promoter region of the EBV lytic gene BZLF1 undergoes modifications, that is, acetylation and phosphorylation of histones upon BCR crosslinking (Jenkins et al., 2000; Countryman et al., 2008) , which seem to be necessary, but not exclusively responsible, for inducing EBV lytic gene expression (Jenkins et al., 2000) . Therefore, we hypothesized that the suppressive effect of TLR9 on lytic EBV may act by blocking acetylation and phosphorylation of histones. Using inhibitors of histone deacetylases (HDACs), we investigated whether the effect of TLR9 triggering on suppression of lytic EBV can be abolished. Indeed, treating Akata cells with trichostatin A (TSA) before TLR9 triggering and BCR crosslinking rescued expression of BZLF1 almost completely (Figure 6a ). Other HDAC inhibitors, including SB, apicidin and scriptaid, also rescued BZLF1 expression (Figures 6c, e and g ). It is noteworthy that SB and scriptaid led to an upregulation and downregulation of BZLF1 expression, respectively, when in combination with BCR crosslinking (Figures 6c and g ). However, CpG2006 did not fully suppress lytic EBV upon treatment with the HDAC inhibitors. In Mutu I cells, treatment with the HDAC inhibitors tested in this study in combination with anti-IgM led to an increase in BZLF1 mRNA levels in comparison with treatment with anti-IgM alone (Figures 6b, d, f and h) . Again, TLR9 triggering did not lead to suppression of BZLF1 when treatment with HDAC inhibitors was performed. These results indicated that the TLR9-mediated suppression of lytic EBV acts by interfering with the acetylation and phosphorylation status of histones.
To verify that TLR9 signaling affects histone modifications on the BZLF1 promoter, we performed chromatin immunoprecipitation (CHIP) analyses in 
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Akata cells. We confirmed that BCR crosslinking leads to an increased amount of phosphorylated histone H3 (Ser10) and acetylated histones H4 and H3 bound to the BZLF1 promoter ( Figure 7) . Moreover, triggering of TLR9 preceding BCR crosslinking decreased levels of phosphorylated and acetylated histones bound to the BZLF1 promoter (Figure 7) . This, together with the TSA experiments (Figure 6 ), strongly suggests that the TLR9-induced histone modifications on the BZLF1 promoter are responsible for suppression of lytic EBV.
TLR9 triggering by its natural ligand hemozoin suppresses induction of lytic EBV
As endemic BL is geographically strongly associated with holoendemic P. falciparum malaria (Rochford et al., 2005) , we investigated whether the malaria pigment hemozoin, a natural ligand of TLR9 (Coban et al., 2005 (Coban et al., , 2009 Parroche et al., 2007) , also leads to suppression of EBV lytic gene expression similar to that observed after treatment with CpG2006. Indeed, treatment of Akata cells with P. falciparum hemozoin (from a crude blood stage extract) preceding BCR crosslinking led to a suppression of BZLF1 transcripts in a dosedependent manner ( Figure 8 ). As crude extracts might stimulate other TLRs than TLR9 (Krishnegowda et al., 2005) , we tested TLR expression and engagement in our BL cell lines with commercially available synthetic ligands. We could not detect any change in BZLF1 expression upon their triggering (data not shown). Thus, TLR9 triggering by its natural ligand P. falciparum hemozoin suppresses induction of lytic EBV.
Discussion
Our aim was to determine the mechanism and the physiological background of the TLR9-mediated suppression of EBV lytic gene expression in BL cells. (3) is independent of TLR9-elicited NF-kB activity as well as other known TLR9 signaling pathways, but (4) involves histone modifications; and (5) P. falciparum hemozoin as the natural ligand for TLR9 triggers suppression of lytic EBV. Thus, our work provides evidence for a possible interaction between P. falciparum and EBV at the B-cell level and the mechanism involved in suppressing lytic EBV and thereby reinforcing latent EBV that has the potential of growth transformation, contributing to BL development. A finding of considerable relevance is our demonstration that P. falciparum hemozoin has the capacity to suppress induction of lytic EBV in Akata cells. This capacity may be mechanistically achieved by histone modifications on the promoter of the EBV master regulatory lytic gene BZLF1, as shown in this study for the synthetic ODN CpG2006 after triggering of TLR9. EBV BZLF1 is repressed by chromatin. The opening of chromatin because of acetylation and phosphorylation of histone tails seems to be a necessary, but in some cell lines not sufficient, step to activate the lytic cycle of EBV. Indeed, although HDAC inhibitors result in acetylation and phosphorylation in all BL cell lines, it may lead to EBV lytic gene expression only in some but not all BL cell lines (Countryman et al., 2008) . The reasons might be the availability, modification or activation of cellular factors that might be necessary to induce the lytic cycle. The cellular background in Mutu I cells distinct from that of Akata cells thus seems to have a crucial role in the inducibility of the lytic phase of EBV . In Mutu I cells, HDAC inhibitors might change the histone structure of the BZLF1 promoter leading to acetylation of histones, or/and might influence the BCR signaling pathway by affecting expression or modification of cellular proteins. Both actions would lead to an enhanced BZLF1 expression and counteract the effect of CpG. Moreover, different HDAC inhibitors have distinct action profiles (de Ruijter et al., 2003) . TSA is a broad-spectrum inhibitor that blocks the activity of class I and class II HDACs, whereas SB inhibits only class I and IIa HDACs. Therefore, the Figure 7 TLR9 signaling induces modifications in histone structure of the EBV lytic promoter BZLF1. Akata cells were treated with CpG2006 and anti-IgG. Harvest of the cells and performance of CHIP assay was followed by PCR for the BZLF1 promoter region. As controls, PCRs for various host and viral promoters regions (Actin, GAPDH, Cp, BdRF1 and BKRF4) were performed, as well as PCR of BZLF1 from the input DNA and a CHIP assay using a control antibody (IgG). One representative experiment is shown out of at least two independent experiments. Density measurement values for BZLF1 compared with a control gene (Actin or GAPDH) are written above the BZLF1 bands. In recent work, we showed that TLR9-mediated suppression of EBV lytic gene expression is not restricted to latently infected cells but can also be observed in ex vivo acutely infected primary cells (Ladell et al., 2007) . This, together with our observation made in this study, indicates that the responsible mechanism is not confined to cells that have undergone malignant transformation but rather may indicate that TLR9-mediated suppression of lytic EBV is likely because of a general mechanism. Interestingly, we could not detect an overt enhanced or reduced proliferation velocity of BL cells upon TLR9 triggering alone (data not shown). This suggests that the mere triggering of TLR9 does not result in promoting proliferation of the malignant cells per se.
Hemozoin, a detoxification product of heme molecules persisting in the food vacuoles of P. falciparum, was shown in this study to reduce EBV lytic BZLF1 expression in vitro. This apparently contrasts the recent findings by Chene et al. (2007) , who showed that P. falciparum CIDR1a might bind to Akata cells in vitro and lead to an increase in the number of cells switching to the viral lytic phase. Nevertheless, the data can be reconciled given that access of hemozoin and CIDR1a to B cells in vivo and the proposed mechanisms of action of the two compounds are distinct. CIDR1a is expressed at the surface of infected erythrocytes, and direct contact between erythrocytes and B cells is required to show a posited mechanism similar to BCR crosslinking (Chene et al., 2007) . In contrast, hemozoin is shed in large amounts after schizont rupture, is not bound to erythrocytes, and thus may disperse more broadly, and be taken up by immune cells in the absence of direct contact with erythrocytes. Furthermore, hemozoin triggers a signaling pathway that does not interfere with BCR crosslinking and it's early signaling as shown in this study. It remains to be investigated whether hemozoin suppresses CIDR1a-induced lytic EBV.
In our assays the natural hemozoin from a crude blood stage extract of the malaria parasite P. falciparum elicited suppression of lytic EBV. It has been a matter of debate whether TLR9 is triggered by hemozoin or malaria DNA that may contaminate crude extracts (Parroche et al., 2007) . However, a recent study unequivocally showed that hemozoin but not malarial DNA can bind TLR9 and elicit an adjuvant effect (Coban et al., 2009) .
Histone modifications after TLR9 triggering, leading to reinforcement of latent EBV, may establish a prerequisite for the development and maintenance of EBV-associated B-cell lymphomas. With respect to endemic BL, one could envision two independent scenarios based on the transformational state of the B cell: in healthy B cells, the continued interaction of P. falciparum and EBV through chronic TLR9 triggering may lead to unbowed latent EBV and thus to increased B-cell survival and risk for transformation; and in transformed endemic BL cells, that is, after c-myc translocation-a hallmark of BL-death of the tumor cells by switching to lytic EBV may be blocked because of TLR9 activation, leading to an increased survival of the EBV-infected malignant cells.
In summary, our data imply that TLR9-MyD88 activation leading to histone modification might be the signaling event responsible for the interaction between the malaria parasite P. falciparum and EBV gene expression in B cells contributing to the pathogenesis of endemic BL. Detailed investigation regarding further TLR9 signaling components responsible for the histone modifications might be beneficial for the engineering of novel interventions that interfere with the development and progression of endemic BL.
Materials and methods
Cell culture and induction of lytic EBV Akata and Mutu I BL cells were cultured as described (Rechsteiner et al., 2008) . Induction of lytic EBV was accomplished with 100 mg/ ml anti-IgG (Dako, DakoCytomation, Zug, Switzerland), 10 mg/ ml anti-IgM (Dako) or 5 ng/ml human TGFb (R&D Systems, Wiesbaden-Nordenstadt, Germany).
Treatment with TLR9 ligands and inhibitors CpG2006 (0.5 mM) or hemozoin (crude blood stage extract from P. falciparum strain 3D7; gift from Hans-Peter Beck and Sebastian Rusch, Basel, Switzerland) treatment preceded induction with anti-IgG, anti-IgM or TGFb for 2 h. IRS869 (5.0 mM) and chloroquine (10 mM; Sigma-Aldrich, Buchs, Switzerland) were added shortly before CpG2006. ODN (Eurogentec, Seraing, Belgium) sequences were as follows: CpG2006 (class B); 5 0 -T*C*G*T*C*G*T*T*T*T*G*T*C*G* T*T*T*T*G*T*C*G*T*T*-3 0 (*bases are phosphorothioate); IRS869, 5 0 -T*C*C*T*G*G*A*G*G*G*G*T*T*G*T*-3 0 (*bases are phosphorothioate), GpC2006 control (LabForce-InvivoGen, Nunningen, Switzerland).
The following signaling inhibitors were applied 1 h before CpG2006: InSolution NF-kB activation inhibitor (Calbiochem) at 1.5 mM; phosphatidylinositol-3 kinase inhibitor Ly294002 (Sigma-Aldrich) at 20 mM; mitogen-activated protein kinase/extracellular signal-regulated kinase kinase inhibitor PD98059 (LabForce-InvivoGen) at 50 mM, c-Jun N-terminal kinase inhibitor SP600125 (Calbiochem) at 20 mM and p38 inhibitor SB203580 (Promega, Madison, WI, USA) at 20 mM. HDAC inhibitors TSA at 50 ng/ml (Sigma-Aldrich Chemie GmbH), SB (Sigma-Aldrich) at 3 mM, apicidin at 1 mM and scriptaid at 7 mM were applied 12 h before CpG2006. Actinomycin D at 2 mg/ml was applied 1 h after anti-IgG treatment, whereas cell harvest was carried out for up to 4 h after actinomycin D treatment.
RNA preparation, reverse transcription and qPCR (TaqMan) RNA isolation, DNAse treatment, reverse transcription and qPCR (TaqMan) was performed as described before (Ladell et al., 2007; Rechsteiner et al., 2008) . BZLF1, BRLF1, BXLF1, BXLF2, BCRF1, MyD88wt, MyD88mutant or hIL10 mRNA expression was normalized to the housekeeping genes mRNA of HMBS, GAPDH or 18sRNA, resulting in D cycle threshold (DC T ) values. As TSA treatment affected HMBS mRNA expression levels, the stable housekeeping gene 18sRNA was chosen for these experiments. DC T values were further normalized as stated in figure   TLR9 triggering in endemic Burkitt's lymphoma L Zauner et al legends. SYBR-Green (Applied Biosystems, Rotkreuz, Switzerland) was used instead of probes for MyD88 measurements.
EBV DNA detection by qPCR (TaqMan) Culture supernatant was passed through a 0.45 mM filter (Millipore, Zug, Switzerland) and was DNAse (Applied Biosystems) treated. DNA extraction from intact virus and qPCR for the EBV conserved BamHI W region was performed as described (Berger et al., 2001) .
Calcium-flux measurements and flow cytometry Cells (1 Â 10 7 /ml À1 ) were treated with CpG2006, followed by Fluo-3 and Fura-Red Dyes final concentrations of 6 and 15 mM, respectively, Invitrogen, Basel, Switzerland) and antiIgG before measurement with a FC-500 (Beckmann-Coulter, Fullerton, CA, USA) for 5 min as a ratio of Fluo-3/Fura Red as described (Novak and Rabinovitch, 1994; Rechsteiner et al., 2008) .
Western blot analyses Washing of cells was followed by incubation on ice for 20 min in 0.5 ml of immunoprecipitation lysis buffer (20 mM Tris-HCl, 50 mM NaCl, 0.1% NP-40, 10 mM b-glycerophosphate, 5 mM NaF, 1 mM phenylmethylsulfonyl fluoride, 2.5% glycerol and 1 complete mini protease inhibitor cocktail tablet (Roche Applied Science, Indianapolis, IN, USA) per 10 ml) and by centrifugation (8000 Â g at 4 1C for 10 min). Immunoprecipitation with monoclonal BZLF1 antibody (1:20; M7005, Dako) and protein G-sepharose beads (product no. P3296; SigmaAldrich) at 4 1C for 24 h was followed by four washes in washing buffer (20 mM Tris-HCl pH 7.5, 50 mM NaCl, 0.1% NP-40 and 1 mM phenylmethylsulfonyl fluoride). The immunoprecipitates were dissolved in Laemmli buffer for separation by sodium dodecyl sulfate-polyacrylamide gel electrophoresis in a 4-12% bis-crosslinked polyacrylamide gel (Invitrogen). After electroblotting at 20 V for 2 h, blocking was performed in 5% milk in Tris-buffered saline, followed by probing for the appropriate antibody in Tris-buffered saline containing 0.1% Tween 20, and staining with chemiluminescence western blotting detection reagents (PerkinElmer, Boston, MA, USA).
Immunofluorescence Akata cells (5 Â 10 5 ) were spun down onto pre-coated Shandon Double Cytoslides (Thermo Electron Corporation, Waltham, MA, USA), dried, fixed in phosphate-buffered saline with 3.7% formaldehyde for 15 min and permeabilized with ice-cold methanol for 2 min. The anti-BZLF1 (Zta) antibody (Argene Biosoft, North Massapequa, NY, USA) was used in a 1:100 dilution and Alexa Fluor 488-or Alexa Fluor 594-conjugated goat anti-rabbit or goat anti-mouse secondary antibodies (Invitrogen) in a 1:1000 dilution.
Cloning and transfection of the MyD88 dominant-negative mutant The plasmid TRIP-MyD88lpr-IRESNEO-WHV containing the MyD88 dominant-negative mutant (MyD88lpr) was a gift from J Tschopp (Lausanne, Switzerland). Digestion with SmaI and NotI resulted in the isolation of the FLAG-MyD88lpr, which was cloned into the polylinker site of the pEneo vectors (Rechsteiner et al., 2007) through PmeI and NotI. Electroporation and selection were performed as described (Rechsteiner et al., 2008) .
CHIP analysis
CHIP was preformed according to the manufacturer's instructions (ChIP-IT Express, Active Motif, Rixensart, Belgium). In brief, 10 7 cells were fixed by formaldehyde. Cells were lysed and homogenized using an ice-cold douncer. Enzymatic shearing was performed for 12.5 min. The sheared chromatin was incubated overnight on a rotating wheel with the antibody of interest and protein G magnetic beads. Washing steps and elution of chromatin was followed by proteinase treatment. PCR analysis at 30-40 cycles was carried out in a 2% agarose gel. The antibodies used were as follows: Phospho-Histone H3 (ser-10) (sc 8656-R; Santa Cruz, Biotechnology, Santa Cruz, CA, USA), anti-acetyl H3 (06-599 Upstate), and anti-acetyl H4 (06-598; Upstate). PCR primers were as follows: BZLF1 reverse ( þ 8) 5
0 -CTCGAGGTGC AATGTTTAGTGAGTTAC-3 0 , BZLF1 forward (-222) 5 0 -GCT AGCGCCATGCATATTTCAACTGGG C-3 0 , BdRF1 and BKRF4 (Jenkins et al., 2000) , Cp (C1) (Alazard et al., 2003) , GAPDH primers (ChIP-IT control kit; Active Motif, Rixensart, Belgium) and Actin forward 5 0 -TGCACTGTGCGGC GAAGC-3 0 and Actin reverse 5 0 -TCGAGCCATAAAAGG CAA-3 0 .
Statistical methods
Level of significance was evaluated using unpaired Student's t-tests or Bonferroni's multiple comparison tests (analysis of variance).
